RE:RE:Cipher Partner, Moberg Pharma Announces Approval for MOB-015The U.S. requires two phase 3 studies for approval. EU does not, if I remember correctly
Moberg is taking advantage of the second phase 3 to try using a shorter treatment period, allowing more recovery time for the nail to recover from the whiteness issue, which would allow them to claim a much higher "complete cure rate".
Even though a nail might be fungus free, the whiteness issue precludes it from being considered "cured" according to the regulatory agencies, so they want to address this.
I sold out of CPH during the past several months, considering it reasonably fairly valued.
GLTA